For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total operating income | - | 0 | - | - |
| Compensation | 845,174 | 1,068,838 | 613,924 | 631,943 |
| Professional fees | 237,916 | 368,932 | 532,235 | 291,812.25 |
| Information technology | 8,175 | 41,835 | 25,317 | 9,664.5 |
| General and administrative-other | 214,181 | 265,449 | 204,236 | 82,415 |
| Total general and administrative costs | 1,305,446 | 1,745,054 | 1,375,712 | 1,015,834.75 |
| Research and development costs, net of grants | 1,216,762 | 802,991 | 575,016 | 467,191.5 |
| Total operating costs | 2,522,208 | 2,548,045 | 1,950,728 | 1,483,026.25 |
| Net operating loss | -2,522,208 | -2,548,045 | -1,950,728 | -1,483,026.25 |
| Interest income/ (expense) | 59,185 | 76,557 | 94,307 | 19,403 |
| Change in fair value of safe | - | - | - | -2 |
| Other income/(expense) | 176,032 | 111,202 | - | -1,708.5 |
| Loss before income taxes | -2,286,991 | -2,360,286 | -1,856,421 | -1,465,333.75 |
| Income taxes | - | 0 | - | - |
| Net loss | -2,286,991 | -2,360,286 | -1,856,421 | -1,465,333.75 |
| Net loss per common share - basic | -0.27 | -0.28 | -0.22 | -0.223 |
| Net loss per common share - diluted | -0.27 | -0.28 | -0.22 | -0.223 |
| Weighted average of common shares outstanding - basic | 8,387,250 | 8,377,265 | 8,367,810 | 1,640,813.75 |
| Weighted average of common shares outstanding - diluted | 8,387,250 | 8,377,265 | 8,367,810 | 1,640,813.75 |
EXOZYMES INC. (EXOZ)
EXOZYMES INC. (EXOZ)